Ankit Mahadevia, CEO and President at Spero Therapeutics, Inc. (SPRO), sold 20 shares at $14.25 ($285) on 2020-10-23, disclosed to the SEC on 2020-10-27.
Scheduled sale ($285) by CEO and President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| SPRO | SELL | 2024-08-29 | $8K | — | Filing → |
| SPRO | SELL | 2024-02-05 | $175K | — | Filing → |
| SPRO | SELL | 2023-08-30 | $11K | — | Filing → |